Randomized, Phase 1/2, Double-blind Pioglitazone Repositioning Trial Combined with Antifungals for the Treatment of Cryptococcal Meningitis - PIO Study

Background: Cryptococcosis affects more than 220,000 patients/year, with high mortality even when the standard treatment [amphotericin B (AMB), 5-flucytosin (5-FC) and fluconazole] is used. AMB presents high toxicity and 5-FC is not currently available in Brazil. In a pre-clinical study, pioglitazone (PIO - an antidiabetic drug) decreased AMB toxicity and lead to an increased mice survival, reduced morbidity and fungal burden in brain and lungs. The aim of this trial is to evaluate the efficacy and safety of PIO combined with standard antifungal treatment for human cryptococcosis.

Methods: A phase 1/2, randomized, double blind, placebo-controlled trial will be performed with patients from Belo Horizonte, Brazil. They will be divided into three groups (placebo, PIO 15 mg/day or PIO 45 mg/day) and will receive an additional pill during the induction phase of cryptococcosis' treatment. Our hypothesis is that treated patients will have increased survival, so the primary outcome will be the mortality rate. Patients will be monitored for survival, side effects, fungal burden and inflammatory mediators in blood and cerebrospinal fluid. The follow up will occur for up 60 days.

Conclusions: We expect that PIO will be an adequate adjuvant to the standard cryptococcosis' treatment.

Trial Registration: ICTRP/WHO (and International Clinical Trial Registry Plataform (ICTRP/WHO) (http://apps.who.int/trialsearch/Trial2.aspx?TrialID=RBR-9fv3f4), RBR-9fv3f4 (http://www.ensaiosclinicos.gov.br/rg/RBR-9fv3f4). UTN Number: U1111-1226-1535. Ethical approvement number: CAAE 17377019.0.0000.5149.

Citing Articles

Synergistic effect of the verapamil and amphotericin B against Cryptococcus neoformans.

Pereira T, do Carmo P, de Menezes R, de Oliveira H, de Oliveira L, Junqueira J Folia Microbiol (Praha). 2023; 68(6):999-1004.

PMID: 37950840 DOI: 10.1007/s12223-023-01104-5.

Cerebral cryptococcoma successfully treated by isavuconazole in an immunocompetent patient: A case report.

Ramanzini L, de Medeiros S, Vieira Lima L, Dos Santos M, Herbster E, Araujo G Radiol Case Rep. 2022; 18(3):824-829.

PMID: 36582749 PMC: 9793169. DOI: 10.1016/j.radcr.2022.11.011.

Pioglitazone Is a Mild Carrier-Dependent Uncoupler of Oxidative Phosphorylation and a Modulator of Mitochondrial Permeability Transition.

Kharechkina E, Nikiforova A, Belosludtsev K, Rokitskaya T, Antonenko Y, Kruglov A Pharmaceuticals (Basel). 2021; 14(10).

PMID: 34681269 PMC: 8537895. DOI: 10.3390/ph14101045.

References

Rodrigues M, Albuquerque P . Searching for a change: The need for increased support for public health and research on fungal diseases. PLoS Negl Trop Dis. 2018; 12(6):e0006479. PMC: 6001980. DOI: 10.1371/journal.pntd.0006479. View

Ghadiany M, Tabarraee M, Salari S, Haghighi S, Rezvani H, Ghasemi S . Adding Oral Pioglitazone to Standard Induction Chemotherapy of Acute Myeloid Leukemia: A Randomized Clinical Trial. Clin Lymphoma Myeloma Leuk. 2019; 19(4):206-212. DOI: 10.1016/j.clml.2019.01.006. View

Spence J, Viscoli C, Inzucchi S, Dearborn-Tomazos J, Ford G, Gorman M . Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. JAMA Neurol. 2019; 76(5):526-535. PMC: 6515584. DOI: 10.1001/jamaneurol.2019.0079. View

Rhein J, Morawski B, Hullsiek K, Nabeta H, Kiggundu R, Tugume L . Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study. Lancet Infect Dis. 2016; 16(7):809-818. PMC: 4927382. DOI: 10.1016/S1473-3099(16)00074-8. View

Chen S, Korman T, Slavin M, Marriott D, Byth K, Bak N . Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii. Clin Infect Dis. 2013; 57(4):543-51. DOI: 10.1093/cid/cit341. View

Hurtado J, Castillo P, Fernandes F, Navarro M, Lovane L, Casas I . Mortality due to Cryptococcus neoformans and Cryptococcus gattii in low-income settings: an autopsy study. Sci Rep. 2019; 9(1):7493. PMC: 6522501. DOI: 10.1038/s41598-019-43941-w. View

Santos-Gandelman J, Rodrigues M, Machado Silva A . Future perspectives for cryptococcosis treatment. Expert Opin Ther Pat. 2018; 28(8):625-634. DOI: 10.1080/13543776.2018.1503252. View

Serghides L, McDonald C, Lu Z, Friedel M, Cui C, Ho K . PPARγ agonists improve survival and neurocognitive outcomes in experimental cerebral malaria and induce neuroprotective pathways in human malaria. PLoS Pathog. 2014; 10(3):e1003980. PMC: 3946361. DOI: 10.1371/journal.ppat.1003980. View

Tolman K, Freston J, Kupfer S, Perez A . Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf. 2009; 32(9):787-800. DOI: 10.2165/11316510-000000000-00000. View

10.

Ryder R . Pioglitazone: reports of its death are greatly exaggerated - it is alive and ready to resume saving lives. Diabet Med. 2015; 32(4):e9-e15. DOI: 10.1111/dme.12736. View

11.

Tenforde M, Shapiro A, Rouse B, Jarvis J, Li T, Eshun-Wilson I . Treatment for HIV-associated cryptococcal meningitis. Cochrane Database Syst Rev. 2018; 7:CD005647. PMC: 6513250. DOI: 10.1002/14651858.CD005647.pub3. View

12.

Dyal J, Akampurira A, Rhein J, Morawski B, Kiggundu R, Nabeta H . Reproducibility of CSF quantitative culture methods for estimating rate of clearance in cryptococcal meningitis. Med Mycol. 2016; 54(4):361-9. PMC: 4834857. DOI: 10.1093/mmy/myv104. View

13.

Chaturvedi V, Chaturvedi S . Cryptococcus gattii: a resurgent fungal pathogen. Trends Microbiol. 2011; 19(11):564-71. PMC: 3205261. DOI: 10.1016/j.tim.2011.07.010. View

14.

Rajasingham R, Smith R, Park B, Jarvis J, Govender N, Chiller T . Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017; 17(8):873-881. PMC: 5818156. DOI: 10.1016/S1473-3099(17)30243-8. View

15.

Santos J, Ribeiro N, Bastos R, Assuncao Holanda R, Silva L, Queiroz E . High-dose fluconazole in combination with amphotericin B is more efficient than monotherapy in murine model of cryptococcosis. Sci Rep. 2017; 7(1):4661. PMC: 5498649. DOI: 10.1038/s41598-017-04588-7. View

16.

Ribeiro N, Santos A, Peres Emidio E, Costa M, Freitas G, Carmo P . Pioglitazone as an adjuvant of amphotericin B for the treatment of cryptococcosis. Int J Antimicrob Agents. 2019; 54(3):301-308. DOI: 10.1016/j.ijantimicag.2019.06.020. View

17.

Young L, Viscoli C, Schwartz G, Inzucchi S, Curtis J, Gorman M . Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. Circulation. 2018; 138(12):1210-1220. PMC: 6202153. DOI: 10.1161/CIRCULATIONAHA.118.034763. View

18.

Cramer C, Alphonse-Sullivan N, Isom S, Metheny-Barlow L, Cummings T, Page B . Safety of pioglitazone during and after radiation therapy in patients with brain tumors: a phase I clinical trial. J Cancer Res Clin Oncol. 2018; 145(2):337-344. PMC: 6805132. DOI: 10.1007/s00432-018-2791-5. View

19.

Capano L, Dupuis A, Brian J, Mankad D, Genore L, Adams R . A pilot dose finding study of pioglitazone in autistic children. Mol Autism. 2018; 9:59. PMC: 6258310. DOI: 10.1186/s13229-018-0241-5. View

20.

Williamson P, Jarvis J, Panackal A, Fisher M, Molloy S, Loyse A . Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. Nat Rev Neurol. 2016; 13(1):13-24. DOI: 10.1038/nrneurol.2016.167. View